Silvercrest Asset Management Group LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 208,028 shares of the company’s stock, valued at approximately $4,583,000. Silvercrest Asset Management Group LLC owned 0.10% of Cellebrite DI at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of CLBT. Polar Capital Holdings Plc raised its holdings in Cellebrite DI by 61.8% in the fourth quarter. Polar Capital Holdings Plc now owns 448,801 shares of the company’s stock valued at $9,887,000 after acquiring an additional 171,404 shares in the last quarter. Man Group plc acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $2,385,000. Nuveen Asset Management LLC raised its holdings in Cellebrite DI by 38.5% in the fourth quarter. Nuveen Asset Management LLC now owns 585,839 shares of the company’s stock valued at $12,906,000 after acquiring an additional 162,886 shares in the last quarter. Lazard Asset Management LLC raised its holdings in Cellebrite DI by 3.7% in the fourth quarter. Lazard Asset Management LLC now owns 197,488 shares of the company’s stock valued at $4,350,000 after acquiring an additional 7,058 shares in the last quarter. Finally, Gen Wealth Partners Inc acquired a new stake in Cellebrite DI in the fourth quarter valued at approximately $85,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Cellebrite DI Stock Down 2.2%
Shares of Cellebrite DI stock opened at $17.02 on Tuesday. The firm has a market capitalization of $4.08 billion, a P/E ratio of -12.24, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The firm’s 50 day moving average is $19.01 and its two-hundred day moving average is $20.25.
Wall Street Analysts Forecast Growth
CLBT has been the topic of several analyst reports. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, May 12th. Finally, Lake Street Capital increased their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $22.43.
Check Out Our Latest Stock Analysis on Cellebrite DI
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
- Five stocks we like better than Cellebrite DI
- Investing in the High PE Growth Stocks
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- With Risk Tolerance, One Size Does Not Fit All
- What Ray Dalio’s Latest Moves Tell Investors
- Investing in Travel Stocks Benefits
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.